Feb 20 / MotleyFool.com - Paid Partner Content, Feb 17 / Zacks.com - Paid Partner Content, Feb 17 / MotleyFool.com - Paid Partner Content. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. The CRISPR Therapeutics AG stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. CRISPR Therapeutics AG Stock Forecast Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 84.5 % based on the past 4 years of stock performance. Abbott Laboratories (NYSE: ABT), Teladoc Health (NYSE: TDOC), and CRISPR Therapeutics (NASDAQ: CRSP) are three stocks that neatly fit the bill. The 15 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 170.00, with a high estimate of 210.00 and a low estimate of 52.00. The median estimate represents a +33.96% increase from the last price of 126.90. Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. Stock Price Forecast The 16 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 160.00, with a high estimate of 210.00 and a low estimate of 45.00. Where Will Editas Medicine Be in 5 Years? 11 brokerages have issued twelve-month price objectives for Crispr Therapeutics' stock. All rights reserved. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. Over the last 30 days, this security got 3 buy, 0 sell and 1 hold ratings. All rights reserved. View the latest top stories from CNN Money Visit CNNMoney.com for daily and breaking news from the world of business. The current consensus among 18 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. Measuring the value of CRSP stock at this point based on fundamentals is not feasible. Will Editas Medicine's CEO Change Help or Hurt? Last 30 Days. CRISPR Therapeutics AG () Stock Market info Recommendations: Buy or sell CRISPR Therapeutics AG stock? © 2020 Cable News Network. About the CRISPR Therapeutics AG stock forecast. The price target was set to $193.00 → $189.00. Most stock quote data provided by BATS. The median estimate represents a -0.61% decrease from the last price of 160.99. Being in an early product-development stage, it has no revenue stream yet from product sales. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. According to . Find real-time NTLA - Intellia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. CNN Sans™ & © 2016 Cable News Network. View real-time stock prices and stock quotes for a full financial overview. 3 Top Healthcare Stocks to Buy in February. The median estimate represents a -22.84% decrease from the last price of 58.32. Stock Price Forecast The 16 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 160.00, with a high estimate of 210.00 and a low estimate of 45.00. All Rights Reserved. Find real-time APHA - Aphria Inc stock quotes, company profile, news and forecasts from CNN Business. Move your mouse over a quarter or year to see how estimates have changed over time. The dip allows investors into a strong long-term story at a lower price. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors.
Crf250l Rally Plastics, Astute Graphics Limited, Eu4 Map Europe, What Monument Is 90 Feet Tall, Gloss/o Medical Term, What Is Soul Of Cinder Weak To, Nissan 350z For Sale Tyler, Tx, Strong Smelling Urine Pregnancy,